Table 3.
Clinical and parasitological response by treatment group for subjects completing follow up
|
Response n(%) |
SP N = 174 |
AS/SP N = 182 |
Total N = 356 |
P* |
| Re-infection | 18 (10.3) | 9 (4.9) | 27 (7.6) | 0.054 |
| Success (ACPR) | 138 (88.5) | 169 (97.7) | 307 (93.3) | 0.0008 |
| Treatment failure | 18 (11.5) | 4 (2.3) | 22 (6.7) | 0.0008 |
| ETF | 5 (3.2) | 3 (1.7) | 8 (2.4) | 0.39 |
| LCF | 4 (2.6) | 0 | 4 (1.2) | 0.03 |
| LPF | 9 (5.8) | 1 (0.6) | 10 (3.0) | 0.006 |
As patients with re-infection were withdrawn and rescued prior to study completion they are excluded form denominators for ACPR and treatment failure
SP: sulphadoxine-pyrimethamine
AS/SP: artesunate/sulphadoxine-pyrimethamine
ACPR: adequate clinical and parasitological response
ETF: early treatment failure
LCF: late clinical failure
LPF: late parasitological failure
*2-sample test of proportions